Puma Biotechnology Publishes Alisertib Abstract Titles for 2024 ASCO Meeting

Puma Biotechnology Inc. (NASDAQ: PBYI), a biopharmaceutical entity, recently unveiled abstracts featuring alisertib that will be showcased at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This significant event is scheduled to occur both in-person at McCormick Place in Chicago and virtually, spanning from May 31 to June 4.

Key abstracts to be presented include:
- Abstract 1037: Titled "Molecular profiling of serial liquid biopsy specimens utilizing cell-free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC 041: A phase II study of alisertib in endocrine-resistant metastatic breast cancer (MBC)." This study will be presented by Dr. Karthik Giridhar from the Mayo Clinic.
- Abstract 8572: Titled "Phase I/Ib study of the aurora kinase A Inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer." Dr. Turja Chakrabarti from the University of California, San Francisco will present this study.

Puma Biotechnology, Inc. is dedicated to the innovation and commercialization of products aimed at improving cancer treatment. The company acquired the global development and commercialization rights for PB272 (neratinib, oral) in 2011. Neratinib received approval from the U.S. Food and Drug Administration (FDA) in July 2017 for extended adjuvant treatment in adult patients with early-stage HER2-positive breast cancer, following trastuzumab-based therapy. It is marketed in the U.S. under the name NERLYNX® (neratinib) tablets. In February 2020, the FDA also approved NERLYNX in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have undergone two or more prior anti-HER2-based treatments in the metastatic setting. The European Commission granted marketing authorization for NERLYNX in September 2018 for the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2-positive breast cancer who are within a year from completing prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma signed an exclusive license agreement for the development and commercialization of alisertib, an orally administered, selective small molecule inhibitor of aurora kinase A. The company's initial focus for alisertib development is on treating small cell lung cancer and breast cancer. February 2024 marked the initiation of ALISCA-Lung 1, a Phase II clinical trial of alisertib monotherapy aimed at treating patients with extensive-stage small cell lung cancer.

Puma Biotechnology continues to be a forward-thinking force in the biopharmaceutical landscape, leveraging innovative solutions to address challenging cancer treatments and improve patient outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!